

NOTIFICATION OF UPCOMING EXPIRY OF UNLISTED OPTIONS

MELBOURNE, Australia, 20 March 2024: Dimerix Limited (ASX: DXB), a biopharmaceutical company with late-stage clinical assets in inflammatory diseases, advises that the Company's Unlisted Options ("Unlisted Options"), which are exercisable into fully paid ordinary DXB shares at \$0.40 each, will expire at 5pm (Sydney time) on 10 April 2024 ("Expiry Date"), being 5.00pm (Sydney time) on the earlier of 30 July 2024 or 20 Business Days after the date that the first Phase 3 FSGS 26 week interim data results are announced on the ASX ("Accelerated Trigger Date").

The Expiry Date is as set out in the terms of issue of the Unlisted Options. The interim data results of the Phase 3 trial were released to ASX on 11 March 2024 and therefore the Expiry Date is 5.00pm (Sydney time) on the Accelerated Trigger Date of 10 April 2024, being the date that is 20 Business Days after release of the interim results to ASX.

Holders of the Unlisted Options can exercise all or part of their holding of Unlisted Options prior to the Expiry Date by completing a Notice of Exercise (that is accessible via the Automic Portal) specifying the number of Unlisted Options being exercised and a payment of cleared funds for the total exercise price for the number of Unlisted Options being exercised.

There is no obligation upon option holders to exercise their Unlisted Options, however Unlisted Options not exercised prior to the Expiry Date will automatically lapse.

For further information, please visit our website at www.dimerix.com or contact:

Dr Nina Webster
Dimerix Limited
Chief Executive Officer & Managing Director
Tel: +61 1300 813 321
E: investor@dimerix.com

Rudi Michelson
Monsoon Communications
Tel: +61 3 9620 3333
Mob: +61 (0)411 402 737
E: rudim@monsoon.com.au

Follow us on [LinkedIn](#) and [Twitter](#)

Authorised for lodgement by the Board of the Company

—END—

About Dimerix

Dimerix (ASX: DXB) is a clinical-stage biopharmaceutical company working to improve the lives of patients with inflammatory diseases, including both kidney and respiratory diseases. Dimerix is currently focussed on developing its proprietary Phase 3 product candidate DMX-200 (QYTOVRA® in some territories), for Focal Segmental Glomerulosclerosis (FSGS) kidney disease, and is also developing DMX-700 for Chronic Obstructive Pulmonary Disease (COPD). DMX-200 and DMX-700 were both identified using Dimerix' proprietary assay, Receptor Heteromer Investigation Technology (Receptor-HIT), which is a scalable and globally applicable technology platform enabling the understanding of receptor interactions to rapidly screen and identify new drug opportunities

Dimerix is a biopharmaceutical company developing innovative new therapies in areas with unmet medical needs.

Dimerix HQ
425 Smith St, Fitzroy 3065
Victoria, Australia
T. 1300 813 321
E. info@dimerix.com